Inclusion Criteria

INCLUSION:

- Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the
following in a patient with clinically documented cirrhosis:

- AFP > 200 mg/dL;

- A contrast-enhancing tumor mass (>1 cm) by CT or MRI; or

- A tumor mass confirmed by arteriography.

- Patient must provide written informed consent and have completed conventional imaging
and staging before initiation of PET imaging.

EXCLUSION:

- Pediatric patients under the age of 18 will be excluded from consideration from this
study.

- Patients with a known prior malignancy (with the exception of basal cell carcinoma of
the skin and carcinoma in situ of the cervix) within 5 years will be excluded from
entry into the study. However, patients with a prior HCC thought to have a new
primary or recurrent HCC are eligible.

- Pregnant and breastfeeding patients.

- Patients with poorly controlled diabetes mellitus (fasting blood glucose level > 200
mg/dL)